<DOC>
	<DOCNO>NCT02819804</DOCNO>
	<brief_summary>The purpose research study determine acceptable upper limit dose nivolumab combination dasatinib may give patient relapsed/refractory philadelphia chromosome positive acute lymphoblastic leukemia ( Ph+ ALL ) . Nivolumab currently Food Drug Administration ( FDA ) approve cancer , yet investigate Ph+ ALL . Dasatinib currently FDA approve treatment Ph+ ALL , yet investigate combination nivolumab disease . There evidence dasatinib block Philadelphia chromosome breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 ( BCR-ABL ) mutation , also increase activity cell immune system . Nivolumab increase T cell immune system , allow immune system attack cancer . We think combination drug effective leukemia either drug use alone .</brief_summary>
	<brief_title>Nivolumab Dasatinib Treating Patients With Relapsed Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) nivolumab give combination dasatinib patient relapsed/refractory Philadelphia chromosome positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) . SECONDARY OBJECTIVES : I . To evaluate toxicity safety profile nivolumab dasatinib patient relapsed/refractory Ph+ ALL . II . To determine rate complete hematologic remission ( CR ) three cycle nivolumab dasatinib . III . To determine rate molecular remission three cycle nivolumab dasatinib . IV . To study pharmacokinetics nivolumab dasatinib . V. To evaluate program cell death 1 ( PD1 ) expression level saturation peripheral blood bone marrow . VI . To measure peripheral T-cell level activation response treatment . TERTIARY OBJECTIVES : I . To evaluate 30 day mortality rate , overall survival ( OS ) , progression free survival ( PFS ) , duration remission ( DOR ) one year treatment nivolumab give combination dasatinib patient relapsed/refractory Ph+ ALL . II . To compare OS patient receive hematopoietic stem cell transplant receive therapy follow remission . III . To evaluate resistance mutation time disease progression . OUTLINE : Patients receive dasatinib orally ( PO ) daily ( QD ) day 1-28 nivolumab intravenously ( IV ) 30 minute day 8 22 course 1 day 1 15 subsequent course . Courses repeat every 28 day absence disease progression , unacceptable toxicity , withdrawal study reason . After completion study treatment , patient follow 30 day monthly 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically confirm diagnosis Ph+ ALL Detection one follow must present : ( 9 ; 22 ) ( q34 ; q11 ) 3way variant metaphase cytogenetics Breakpoint cluster region ( BCR ) Abelson ( ABL ) positive status molecular analysis qualitative polymerase chain reaction ( PCR ) fluorescence situ hybridization ( FISH ) Patients must primary refractory ALL base failure achieve hematologic molecular remission induction therapy dasatinib steroid dasatinib chemotherapy , relapse treatment tyrosine kinase inhibitor without chemotherapy Note : Prior course dasatinib steroid induction therapy include dasatinib 140mg PO daily day 184 prednisone 60mg/m^2 ( cap 120mg , equivalent steroid dose ) day 128 ; patient unable tolerate full steroid dose induction therapy still eligible Note : Patients refractory relapsed disease central nervous system eligible Prior chemotherapy tyrosine kinase inhibitor ( TKI ) treatment , aside dasatinib , must &gt; = 7 day first investigational agent dose Patients must exhibit Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Patients must adequate organ bone marrow function prior registration , define : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2 x institutional upper limit normal ( IULN ) Total bilirubin &lt; 2.0 x IULN ( unless Gilbert syndrome diagnose ) ; leukemia infiltration liver suspect cause liver function abnormality patient still eligible principal investigator ( PI ) approval Creatinine &lt; 2 x IULN Creatinine clearance &gt; 40 mL/min ( measure CockroftGault ) Females childbearing potential ( FOCBP ) must negative pregnancy test within 7 day registration Note : A FOCBP woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : Has undergone hysterectomy bilateral oophorectomy Has menses time precede 12 consecutive month ( therefore naturally postmenopausal &gt; 12 month ) Women must breastfeed time study registration Women men reproductive potential agree use two effective mean birth control For woman , contraception continue 23 week last dose nivolumab 12 week last dose dasatinib allow complete clearance drug principal metabolite body For men , contraception continue 31 week nivolumab 12 week dasatinib Patients must ability understand willingness sign write informed consent prior registration study Patients may receive investigational agent within 5 halflives drug ( know ) ; halflife know , investigational agent take within two week Patients eligible intolerance recent prior TKI ( dasatinib ) low possible effective dose , define grade &gt; = 3 toxicity consider least possibly related TKI ; patient also exclude intolerant allergic dasatinib discontinue prior therapy due &gt; = grade 2 treatment related adverse event Patients must history grade 4 anaphylactic reaction monoclonal antibody therapy know hypersensitivity reaction drug formulate polysorbate 90 Patients must prior therapy antiPD1 , antiprogrammed cell death 1 ligand 1 ( PDL1 ) , antiprogrammed cell death 1 ligand 2 ( PDL2 ) , anticluster differentiation ( CD ) 137 anticytotoxic tlymphocyteassociated protein 4 ligand ( CTLA4 ) antibody ( antibody drug specifically target Tcell costimulation checkpoint pathway ; question uncertainty , please contact PI quality assurance manager ( QAM ) Patients allogeneic hematopoietic stem cell transplant ( HSCT ) eligible meet follow : transplant within 2 month cycle 1 , day 1 ( C1D1 ) Has clinically significant graftversushost disease require treatment Has &gt; = grade 3 persistent nonhematological toxicity relate transplant Concomitant use strong inhibitor cytochrome p450 , family 3 , subfamily , polypeptide 4 ( CYP3A4 ) isoenzyme permit ; must washout period 5 time halflife compound first dasatinib dose Concomitant use QT prolonging agent strongly associate torsades de pointes permit Patients know dasatinibresistant ABLkinase mutation T315I eligible ; confirmation , please contact PI Patients serious uncontrolled medical disorder would impair ability subject receive protocol therapy eligible ; include , limited : Active infection well control Known pleural pericardial effusion baseline Clinically significant gastrointestinal disease digestive dysfunction compromise absorption dasatinib Pulmonary arterial hypertension Uncontrolled significant cardiovascular disease , include : Myocardial infarction within 6 month enrollment date Uncontrolled angina congestive heart failure within 3 month enrollment date Left ventricular ejection fraction ( LVEF ) &lt; 40 % Significant cardiac conduction abnormality , include : History clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , torsades de pointes ) History second third degree heart block ( except second degree type 1 ) Corrected QT ( QTc ) interval &gt; 500 msec , unless cardiac pacemaker present Prior malignancy active within previous 3 year , except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ prostate , cervix breast Subjects active , know suspected autoimmune disease ; ( Note : Subjects vitiligo , type I diabetes mellitus , hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll ) Psychiatric illness/social situation would limit compliance study requirement Any illness condition treat investigator feel would interfere study compliance would compromise patient 's safety study endpoint Female patient pregnant nursing eligible Patients eligible know positive test hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( hepatitis C virus [ HCV ] antibody ) indicate acute infection ; Note : Patients evidence chronic hepatitis B infection allow enroll appropriate suppressive medication direction hepatologist PI approval Patients know positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) eligible Patients must live vaccine therapy prevention infectious disease within 28 day first nivolumab dose Patients unable swallow oral medication eligible Patients active autoimmune disease history autoimmune disease might recur , may affect vital organ function require immune suppressive treatment include chronic prolonged systemic corticosteroid ( define corticosteroid use duration one month great ) , exclude ; include limited patient history : Immune relate neurologic disease Multiple sclerosis Autoimmune ( demyelinate ) neuropathy GuillainBarre syndrome Myasthenia gravis Systemic autoimmune disease systemic lupus erythematosus ( SLE ) Connective tissue diseases Scleroderma Inflammatory bowel disease ( IBD ) Crohn 's Ulcerative colitis Patients history toxic epidermal necrolysis ( TEN ) StevensJohnson syndrome Antiphospholipid syndrome NOTE : Subjects vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>